Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lysogene SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Lysogene Raises USD22.6 Million in Series A Financing 11
Partnerships 12
Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12
Alcyone Lifesciences Enters into Agreement with Lysogene 13
Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14
Licensing Agreements 15
Sarepta Therapeutics Enters into License Agreement with Lysogene 15
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16
Equity Offering 17
Lysogene Raises USD24.3 Million in IPO 17
Lysogene SAS – Key Competitors 18
Lysogene SAS – Key Employees 19
Lysogene SAS – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Apr 16, 2018: Lysogene Reports First Quarter Financial Results and Provides Business Update 21
Mar 26, 2018: Lysogene: 2017 annual results 22
Jan 15, 2018: Lysogene Reports Fourth Quarter 2017 Financial Information 24
Oct 16, 2017: Lysogene: Financial Information for the Third Quarter of 2017 25
Sep 19, 2017: Lysogene Announces First Half 2017 Financial Results and Business Update 26
Jul 12, 2017: Lysogene: Financial Information for the Second Quarter of 2017 28
Apr 21, 2017: Lysogene: 2016 annual results 29
Apr 12, 2017: Lysogene: financial information for the 1st quarter of 2017 30
Corporate Communications 31
Sep 13, 2018: Lysogene announces changes in the composition of its Board of Directors 31
May 15, 2018: Lysogene Nominates Dr Ralph Laufer As Chief Scientific Officer And Member Of Executive Team 32
Apr 23, 2018: Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen 33
Sep 12, 2017: Lysogene Launches World Class Clinical Advisory Board 34
May 16, 2017: Lysogene Reinforces Its Management Team With the Nomination of Philippe Mendels-flandre as Chief Operating Officer 35
Product News 36
10/05/2017: Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City 36
Sep 21, 2017: Lysogene Holds First Parent Advisory Board in MPS IIIA 37
08/01/2018: Lysogene announces upcoming presentations at the 2018 international MPS symposium 38
03/28/2017: Lysogene Announces Baseline Data From First International Pivotal Observational Study In MPS IIIA 39
02/01/2018: Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposium 40
Product Approvals 41
Feb 06, 2018: Lysogene gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals 41
Feb 21, 2017: Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis 42
Feb 02, 2017: Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101 for treatment of GM1 Gangliosidosis 43
Jan 18, 2017: Lysogene Receives Rare Pediatric Disease Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis 44
Clinical Trials 45
May 30, 2017: Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA 45
Other Significant Developments 46
Jul 23, 2018: Lysogene reports second quarter cash position and provides business and strategic update 46
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
Lysogene SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Deals By Therapy Area, 2012 to YTD 2018 9
Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lysogene Raises USD22.6 Million in Series A Financing 11
Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12
Alcyone Lifesciences Enters into Agreement with Lysogene 13
Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14
Sarepta Therapeutics Enters into License Agreement with Lysogene 15
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16
Lysogene Raises USD24.3 Million in IPO 17
Lysogene SAS, Key Competitors 18
Lysogene SAS, Key Employees 19
List of Figures
Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9